Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial

OBJECTIVE: To test the hypothesis that ticagrelor plus aspirin is safe and superior to clopidogrel plus aspirin for reducing high platelet reactivity at 90 days and stroke recurrence in patients with minor stroke or transient ischaemic attack, particularly in carriers of the CYP2C19 loss-of-function...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yilong, Chen, Weiqi, Lin, Yi, Meng, Xia, Chen, Guohua, Wang, Zhimin, Wu, Jialing, Wang, Dali, Li, Jianhua, Cao, Yibin, Xu, Yuming, Zhang, Guohua, Li, Xiaobo, Pan, Yuesong, Li, Hao, Zhao, Xingquan, Liu, Liping, Lin, Jinxi, Dong, Kehui, Jing, Jing, Johnston, S Claiborne, Wang, David, Wang, Yongjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group Ltd. 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549283/
https://www.ncbi.nlm.nih.gov/pubmed/31171523
http://dx.doi.org/10.1136/bmj.l2211

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549283/
https://www.ncbi.nlm.nih.gov/pubmed/31171523
http://dx.doi.org/10.1136/bmj.l2211

Ejemplares similares